Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1995 2
1996 2
1998 1
2001 2
2013 1
2018 1
2019 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Acarbose-associated hepatotoxicity.
Andrade RJ, Lucena M, Vega JL, Torres M, Salmerón FJ, Bellot V, García-Escaño MD, Moreno P. Andrade RJ, et al. Among authors: salmeron fj. Diabetes Care. 1998 Nov;21(11):2029-30. doi: 10.2337/diacare.21.11.2029. Diabetes Care. 1998. PMID: 9802764 Review. No abstract available.
Benzylpenicillin-induced prolonged cholestasis.
Andrade RJ, Guilarte J, Salmerón FJ, Lucena MI, Bellot V. Andrade RJ, et al. Among authors: salmeron fj. Ann Pharmacother. 2001 Jun;35(6):783-4. doi: 10.1345/aph.10266. Ann Pharmacother. 2001. PMID: 11409000 No abstract available.
Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.
Turnes J, Rincón D, Calleja JL, Delgado MB, Rosales JM, Andrade RJ, Manzano ML, Salmerón FJ, López MA, Calvo M, Gómez J, Molina E, Frias YN, Gálvez-Fernández RM, Vallejo-Senra N, París S, Santos de Lamadrid R, Olveira A. Turnes J, et al. Among authors: salmeron fj. Gastroenterol Hepatol. 2022 May;45(5):342-349. doi: 10.1016/j.gastrohep.2021.05.015. Epub 2021 Jun 12. Gastroenterol Hepatol. 2022. PMID: 34129903 English, Spanish.
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort.
Hernández-Conde M, Fernández I, Perelló C, Gallego A, Bonacci M, Pascasio JM, Romero-Gómez M, Llerena S, Fernández-Rodríguez C, Castro Urda JL, García Buey L, Carmona I, Morillas RM, García ND, Gea F, Carrión JA, Castellote J, Moreno-Planas JM, Piqueras Alcol B, Molina E, Diago M, Montoliu S, de la Vega J, Menéndez F, Sánchez Ruano JJ, García-Samaniego J, Rosales-Zabal JM, Anton MD, Badia E, Souto-Rodríguez R, Salmeron FJ, Fernández-Bermejo M, Figueruela B, Moreno-Palomares JJ, Calleja JL. Hernández-Conde M, et al. Among authors: salmeron fj. J Viral Hepat. 2019 Jan;26(1):55-64. doi: 10.1111/jvh.13008. Epub 2018 Oct 25. J Viral Hepat. 2019. PMID: 30265418
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
Wedemeyer H, Jensen D, Herring R Jr, Ferenci P, Ma MM, Zeuzem S, Rodriguez-Torres M, Bzowej N, Pockros P, Vierling J, Ipe D, Munson ML, Chen YC, Najera I, Thommes J; PROPEL Investigators. Wedemeyer H, et al. Hepatology. 2013 Aug;58(2):524-37. doi: 10.1002/hep.26274. Epub 2013 Jun 26. Hepatology. 2013. PMID: 23348636 Clinical Trial.
11 results